FORM	4
------	---

Check this box if no
longer subject to
Section 16. Form 4 or
Form 5 obligations may
continue. See
Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)											
1. Name and Address of Reporting Person [*] 2. Issuer Name and Ticker or Trading Symbol Erfanian Hamid ENZO BIOCHEM INC [ENZ]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
(Last) (First) C/O ENZO BIOCHEM, INC., 527 MA AVENUE	DIGONI	3. Date of Earliest Transaction (Month/Day/Year) 06/15/2022						X Officer (give title below) Other (specify below) Chief Executive Officer			
(Street) NEW YORK, NY 10022	4	4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City) (State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned									
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution Date, if	Code ((Instr. 8) (4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) (A) or Amount (D) Price		of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership	
Common Stock, \$0.01 Par Value	06/15/2022		P	•		A	\$ 2.19	274,600	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in SEC 1474 (9-02) this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)															
	Conversion	Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code)		A) d of	6. Date Exercisable and Expiration Date of Underlying (Month/Day/Year) Securities (Instr. 3 and 4)		ng	Security (Instr. 5) Beneficially Owned Following		ivative Ownership arities Form of eficially Derivative ned Security: owing Direct (D) orted or Indirect		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
Stock Option (to acquire Common Stock)	\$ 3.39	11/08/2021		А		700,000		11/08/2022	11/08/2026	Common Stock	700,000	\$ 0	700,000 (1)	D	

Reporting Owners

	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
Erfanian Hamid C/O ENZO BIOCHEM, INC. 527 MADISON AVENUE NEW YORK, NY 10022			Chief Executive Officer					

Signatures

/s/ Hamid Erfanian	06/17/2022
**Signature of Reporting Person	Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The Reporting Person was granted 700,000 stock options. The stock options have a five-year term and will vest, subject to the individual's continued employment with Enzo Biochem, Inc., in (1) three equal annual installments, beginning on November 8, 2022.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.